Filed - Glenmark

NCE Pipeline
Lead Target Indication Stage Status
GRC 3886
(Oglemilast)
PDE 4
Asthma,
COPD
Ph II
• Currently 2 Ph II trials underway for “exercise
induced asthma” and “antigen challenge”;
enrollment complete for the first study, top line
results likely by Nov FY07
• Phase II B for Asthma, COPD likely to begin
early next year
• Survey by R&D Directions classified GRC 3886
as one of the Great 100 Investigational Drugs
• $ 30 Mn expected from Forest Inc.,
• In discussions with potential European Partners
GRC 8200
DPP IV
Diabetes
(Type II)
Ph II
• 2 Ph II trials underway in South Africa and India
• Tied up with Merck KGaA of Germany in Oct 06
to develop, register and commercialize GRC
8200 and its combinations in US, Europe, Japan
• Glenmark retains exclusive marketing rights for
India and will co-commercialize the drug in RoW
• Total deal size is EUR 190 Mn, with EUR 25 Mn
as an up-front payment and the remaining
milestone payments upon successful
development, launch
• Upon commercial launch, Glenmark will supply
the API to Merck KGaA and will receive royalties
on net sales of the product
9